Becton Dickinson and Co (BDX) : Mcqueen Ball Associates scooped up 70 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 15,625 shares of Becton Dickinson and Co which is valued at $2,713,594.Becton Dickinson and Co makes up approximately 1.88% of Mcqueen Ball Associates’s portfolio.
Other Hedge Funds, Including , Pennsylvania Trust Co boosted its stake in BDX in the latest quarter, The investment management firm added 310 additional shares and now holds a total of 4,488 shares of Becton Dickinson and Co which is valued at $788,901. Becton Dickinson and Co makes up approx 0.06% of Pennsylvania Trust Co’s portfolio.Capital Analysts boosted its stake in BDX in the latest quarter, The investment management firm added 870 additional shares and now holds a total of 14,030 shares of Becton Dickinson and Co which is valued at $2,446,832. Becton Dickinson and Co makes up approx 0.48% of Capital Analysts’s portfolio.
Becton Dickinson and Co opened for trading at $175.19 and hit $176.33 on the upside on Wednesday, eventually ending the session at $175.78, with a gain of 0.72% or 1.26 points. The heightened volatility saw the trading volume jump to 5,08,577 shares. Company has a market cap of $37,301 M.
On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.